Skip to content

Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute Leukemia

Emotion And Symptom-focused Engagement (EASE): A Randomized Pilot Trial of an Intervention for Individuals With Acute Leukemia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02353559
Acronym
EASE
Enrollment
47
Registered
2015-02-02
Start date
2015-03-31
Completion date
2016-11-30
Last updated
2019-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Leukemia

Keywords

acute leukemia, traumatic stress, quality of life, symptom burden, psychosocial oncology, palliative care, intervention, hematological malignancies, supportive care

Brief summary

The purpose of this study is to test the feasibility of an individual psychological and physical symptom intervention, called Emotion And Symptom-focused Engagement (EASE), to reduce traumatic stress and physical symptom burden in individuals newly diagnosed with acute leukemia.

Detailed description

This study involves the pilot-testing of a newly developed, brief manualized individual psychotherapy and physical symptom control intervention, called Emotion And Symptom-focused Engagement (EASE), to reduce traumatic stress and physical symptom burden in individuals newly diagnosed with acute leukemia. The purpose of this study is to conduct a two-arm randomized pilot trial (RPT) to test the feasibility, acceptability, and preliminary efficacy of EASE against usual care (UC) for the reduction of traumatic stress and physical symptom burden in patients with acute leukemia. Usual care for individuals with acute leukemia treated at the Princess Margaret Cancer Centre includes referral for non-standardized, and primarily instrumental, psychosocial care and palliative care service as needed. The design will be an unblinded RPT consisting of two conditions (EASE and UC), with a baseline assessment and follow-ups at 4, 8, and 12 weeks. The trial will take place at the Princess Margaret Cancer Centre, University Health Network; a comprehensive cancer center in Toronto, Canada. Participants will be newly diagnosed with acute leukemia, within one month of diagnosis and/or admission to hospital for treatment with curative intent.

Interventions

BEHAVIORALEASE

EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.

Sponsors

Canadian Cancer Society (CCS)
CollaboratorOTHER
University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* new or relapsed diagnosis of acute leukemia (an amendment to allow recruitment of relapsed patients was approved on 24-Sep-2015, although no relapsed patients were ultimately recruited) * will be receiving induction chemotherapy with curative intent and within 1 month of diagnosis and/or admission to hospital at the Princess Margaret Cancer Centre * age ≥ 18 years * fluency in English * no cognitive impairment indicated in the medical record, communicated by the hematology clinical team, or determined by research staff at recruitment.

Exclusion criteria

* inability to pass the cognitive screening test (Short Orientation-Memory Concentration Test \[SOMC\] score \<20) * actively receiving psychological/psychiatric counseling or palliative care services from the Department of Psychosocial Oncology and Palliative Care (POPC), now called the Department of Supportive Care, at the Princess Margaret Cancer Centre at the time of recruitment to this study

Design outcomes

Primary

MeasureTime frameDescription
Stanford Acute Stress Reaction Questionnaire (SASRQ)12 weeksA 30-item reliable and valid self-report measure of traumatic stress symptoms.

Secondary

MeasureTime frameDescription
Beck Depression Inventory-II (BDI-II)12 weeksA 21-item reliable and valid self-report measure of the intensity of depressive symptoms, consistent with the DSM-V criteria for major depressive disorder.
Brief Pain Inventory short form (BPI-sf)12 weeksA 9-item reliable and valid self-report measure that assesses pain severity and the impact of pain on daily functioning.
Memorial Symptom Assessment Scale (MSAS)12 weeksA 32-item reliable and valid self-report inventory assessing the presence and severity of 26 common physical symptoms and 6 psychological symptoms of cancer. The scale has been adapted to reduce burden. A shortened version that omits frequency of symptoms and treatment, and satisfaction with treatment for each symptom was used.
Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale (FACIT-Sp)12 weeksA 40-item reliable and valid self-report measure of overall quality of life, including 12 items that assess spiritual well-being, spiritual meaning and peace, and faith.
FAMCARE-P1612 weeksA 16-item reliable and valid self-report measure of patient satisfaction with healthcare providers.
Clinical Evaluation Questionnaire (CEQ)12 weeksA 7-item measure developed for this study to evaluate the extent to which patients felt emotionally supported by the clinical services provided.
Edmonton Symptom Assessment System - Acute Leukemia (ESAS-AL)24 hoursA 14-item symptom severity assessment measure adapted for patients with acute leukemia to include prevalent and treatable symptoms in this population: mouth sores, diarrhea, itching, constipation, and insomnia. ESAS-AL was used as a screening tool as part of the clinical intervention, and was added as an outcome later in the trial (13-Apr-2016).
Brief Experiences in Close Relationships Scale (ECR-M16)12 weeksA 16-item reliable and valid self-report measure of attachment security.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026